Comparative Safety and Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide Prior to Chimeric Antigen Receptor- T cell Therapy: A Systematic Review and Meta-Analysis | Synapse
March 3, 2026
Comparative Safety and Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide Prior to Chimeric Antigen Receptor- T cell Therapy: A Systematic Review and Meta-Analysis
Puntos clave
Bendamustine shows comparable safety and efficacy to fludarabine/cyclophosphamide before CAR-T therapy.
The analysis includes data from multiple studies assessing therapeutic outcomes across various populations.
This systematic review and meta-analysis examined outcomes like response rates and toxicities with specific comparative treatments.
Understanding these treatments' effectiveness can guide critical decisions in administering CAR-T therapy; more studies are needed.